Dr. Kaag is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office500 University Drive
Hershey, PA 17033Phone(717) 531-8521Fax(717) 531-4475
- Is this information wrong?
- Dr. Kaag is a board certified urologist who completed a urologic oncology fellowship at Memorial Sloan-Kettering Cancer Center in 2010. His practice focuses on the surgical management of patients with complex or advanced urologic cancers. He co-leads the Genitourinary Cancer Team at the Penn State Cancer Insitute and coordinates multidisciplinary cancer care for his patients. His clinical interests include bladder cancer, locally advanced kidney cancer, penile cancer, and testicular cancer. His research focuses on understanding barriers to recovery following radical cystectomy for bladder cancer.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2007 - 2010
- Penn State Milton S Hershey Medical CenterResidency, Urology, 2003 - 2007
- Penn State Milton S Hershey Medical CenterInternship, Transitional Year, 2002 - 2003
- Pennsylvania State University College of MedicineClass of 2002
Certifications & Licensure
- NY State Medical License 2007 - 2010
- PA State Medical License 2002 - 2022
- American Board of Urology Urology
- ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder Start of enrollment: 2017 Nov 21
Phase 1, Phase 2
Publications & Presentations
- Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?R. Grant Owens, Justin Loloi, Erik Lehman, Matthew Kaag, Jay D. Raman, Suzanne B. Merrill> ;Urologic Oncology-seminars and Original Investigations. 2021 Feb 17
- 2 citationsHistologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass BiopsyLauren M Nahouraii, Jordan L Allen, Suzanne B. Merrill, Erik Lehman, Matthew Kaag, Jay D. Raman> ;Journal of Kidney Cancer and VHL. 2020 Aug 25
- Can preoperative imaging characteristics predict pT3 bladder cancer following cystectomyJay Fuletra, Andrew Watts, Matthew Kaag, Erik Lehman, Jay D. Raman, Suzanne B. Merrill> ;World Journal of Urology. 2021 Jun 1
- Join now to see all
- Original Contribution Mitotic Activity in Non-Invasive Papillary Urothelial Carcinoma: Its Value in Predicting Tumor Recurrence, and Comparison to the Contemporary Two...Augustyna Gogoj, Suzanne B Merrill, Monika Joshi, Sheldon Holder, Joshua I Warrick, Matthew Kaag, Jay D Raman, Joseph Drabick, ScienceDirect
- Predicted Versus Observed 30-Day Perioperative Outcomes Using the ACS NSQIP Surgical Risk Calculator in Patients Undergoing Partial Nephrectomy for Renal Cell CarcinomaBrian M Blair, Jay D Raman, Matthew G Kaag, International Urology and Nephrology
- Detecting and Treating Urologic Cancers with Penn State Hershey Cancer InstituteSeptember 8th, 2015
- Enhancing Patient Resilience During Multimodal Therapy for Bladder CancerWells Fargo Barsumian Trust2013–2014
- Mid-Atlantic Section, AUAMember
- Urologic Oncology Research AllianceChair
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: